Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Neural Correlates of Anti-suiciDal rEsponse to kEtamine in Treatment Resistant biPolar dePression (DEEPP-Study)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05177146

Organisation Name: Centre for Addiction and Mental Health

Overal Status: Not yet recruiting

Start Date: February 19, 2022

Last Update: January 4, 2022

Lead Sponsor: Centre for Addiction and Mental Health

Brief Summary: Bipolar disorder is characterized by manic episodes and episodes of extreme depressive feelings, also known as bipolar depression (BD). Although clinical data does not suggest significant differences in the severity of depressive symptoms between bipolar and unipolar depression, patients with BD are found to be more likely to experience suicidal ideation and suicide attempts. Innovative treatments for suicidality in patients with BD are needed to address tolerability and slow effect limitations of current interventions. Using an open label pilot study, this trial aims to examine the effect of Intravenous (IV) ketamine treatment on acute suicidality in patients with BD. Moreover, the study aims to explore the neurophysiological mechanisms of ketamine's action directly from the cortex in patients with BD, in order to understand the biological mechanism underlying ketamine's therapeutic action.

Conditions:
  • Bipolar Disorder (BD)
  • Suicidality


Total execution time in seconds: 0.20333409309387